Union Bancaire Privee UBP SA Decreases Stock Holdings in Eli Lilly and Company $LLY

Union Bancaire Privee UBP SA reduced its stake in shares of Eli Lilly and Company (NYSE:LLY) by 3.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 84,298 shares of the company’s stock after selling 3,199 shares during the period. Eli Lilly and Company accounts for about 1.4% of Union Bancaire Privee UBP SA’s portfolio, making the stock its 13th largest holding. Union Bancaire Privee UBP SA’s holdings in Eli Lilly and Company were worth $92,477,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in LLY. Roxbury Financial LLC boosted its stake in Eli Lilly and Company by 10.0% during the fourth quarter. Roxbury Financial LLC now owns 264 shares of the company’s stock worth $284,000 after buying an additional 24 shares during the last quarter. Foguth Wealth Management LLC. acquired a new stake in shares of Eli Lilly and Company in the 4th quarter worth $734,000. Marathon Mission Inc. acquired a new stake in shares of Eli Lilly and Company in the 4th quarter worth $229,000. GAMMA Investing LLC raised its holdings in shares of Eli Lilly and Company by 27.0% during the 4th quarter. GAMMA Investing LLC now owns 21,821 shares of the company’s stock worth $23,451,000 after acquiring an additional 4,641 shares during the period. Finally, First Financial Bank Trust Division boosted its position in shares of Eli Lilly and Company by 4.2% during the 4th quarter. First Financial Bank Trust Division now owns 1,447 shares of the company’s stock valued at $1,555,000 after acquiring an additional 58 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the topic of a number of analyst reports. Zacks Research downgraded shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 30th. The Goldman Sachs Group set a $1,260.00 price target on shares of Eli Lilly and Company in a report on Thursday, February 5th. HSBC lowered shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and reduced their price target for the company from $1,070.00 to $850.00 in a research report on Tuesday. Wall Street Zen cut Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Finally, Royal Bank Of Canada started coverage on Eli Lilly and Company in a research note on Tuesday, February 24th. They issued an “outperform” rating and a $1,250.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $1,221.44.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: TRANSCEND‑T2D‑1 Phase 3: Lilly’s triple‑agonist retatrutide showed large A1C reductions and up to ~16.8% weight loss at 40 weeks — a potential blockbuster that expands Lilly’s obesity/diabetes franchise and supports long‑term revenue upside. Lilly PR Newswire
• Positive Sentiment: ADorable‑1 pediatric trial: Positive topline results for EBGLYSS in moderate‑to‑severe atopic dermatitis pediatric patients widen Lilly’s immunology pipeline and add another potential near‑term commercial opportunity. InsiderMonkey: ADorable‑1
• Positive Sentiment: High‑profile endorsement: Jim Cramer publicly said “buy” on Lilly, which can boost retail demand and sentiment in the near term. Yahoo Finance: Cramer
• Neutral Sentiment: Pipeline breadth: Lilly advanced non‑GLP‑1 programs (digital sleep tech in early Alzheimer’s, a new diabetes candidate in Japan, and a master IBD trial), which diversify long‑term growth but have limited immediate revenue impact. TipRanks: Digital Sleep Tech
• Negative Sentiment: Analyst downgrades and rating cuts: Recent downgrades (HSBC and others) have pressured sentiment and contributed to near‑term share weakness. AmericanBankingNews: Analyst Downgrade
• Negative Sentiment: Competitive and safety concerns: Novo Nordisk won FDA clearance for a higher‑dose Wegovy (raising competitive risk in obesity), and some reports flagged an unusual skin reaction/tolerability signal for retatrutide — both factors that can temper uptake forecasts and invite closer regulatory/physician scrutiny. Blockonomi: Wegovy dose Proactive: Retatrutide side‑effect note

Eli Lilly and Company Stock Performance

NYSE LLY opened at $905.30 on Friday. The company has a debt-to-equity ratio of 1.54, a current ratio of 1.58 and a quick ratio of 1.19. The company has a market cap of $855.35 billion, a P/E ratio of 39.45, a P/E/G ratio of 1.07 and a beta of 0.40. The stock has a 50-day moving average of $1,023.17 and a two-hundred day moving average of $956.18. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, beating the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. During the same quarter last year, the firm posted $5.32 earnings per share. The business’s revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.